Pharmsynthez PJSC Secures RUB 800m With LDA Capital
24.6.2021 08:00:00 EEST | Business Wire | Press release
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months, including those aimed at combating COVID-19.
Both Pharmsynthez and LDA view this capital allocation not only as an investment into the Company but also as a starting point for a long-term strategic partnership to advance Pharmsynthez’s promising projects in the field of innovative pharmaceutical technologies and development of the latest treatments for complex diseases.
LDA Capital’s investments will accelerate Pharmsynthez PJSC projects in all aspects. The Company’s business plan until 2025 allows for the introduction of several highly profitable original drugs (Epolong® and other finished dosage forms) to the domestic market, an increase in the production of active pharmaceutical ingredients, and the launch of the new drugs, such as vaccines that solve various purposes, including: treatment of multiple sclerosis (Xemys®), prevention of hepatitis B (Sci-B-Vac®), COVID-19 and a number of other diseases. In addition, the Company is preparing to bring to market and then localize the production of several generic drugs for the treatment of orphan and oncological diseases, as well as to launch the production of monoclonal antibodies drugs and dry cell culture media for the pharmaceutical industry, becoming a leader in the EAEU market.
Efim Prilezhaev, General Director of Pharmsynthez PJSC, commented: “We are pleased that our partnership with LDA Capital as one of the most successful progressive investors in an environment where interest in pharmaceutical technologies is at an all-time high. Nowadays, the growing demand for innovative developments in the field of biotechnology, the growing risks of pandemics and infectious diseases provide significant growth opportunities for players in this difficult market. We are confident that our partnership with LDA will help deliver outstanding results for the benefit of society.”
Warren Baker, the Managing Partner of LDA Capital, stated: “On the back of secular growth trends in cell culture-based vaccines and monoclonal antibodies (mAb), LDA is enthused to partner with one of the leading Russian pharmaceutical manufacturers. We are excited by Pharmsynthez’s scientific potential and look forward to our continuous cooperation as we remain steadfast on our commitment to providing alternative capital solutions to innovative companies in the global healthcare sector.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005990/en/
Contact information
Robert Baker
LDA Capital
323-471-4325
rbaker@ldacap.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 16:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key Highlights Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*2. Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorpo
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom